Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Bayer Schering Pharma patents sGC activators/PDE5 inhibitors

March 10, 2016

CaM-dependent RyR2 inhibitor shows promise for the treatment of arrhythmias

March 4, 2016

Phase II trial of danegaptide for cardiac reperfusion injuries does not meet primary endpoint

March 3, 2016

Modified version of troponin C modulates cardiac contractility in vivo

March 2, 2016

Intra-Cellular Therapies presents PDE1A and/or PDE1C inhibitors

March 1, 2016

AstraZeneca and CMS sign agreements regarding Plendil and Imdur

March 1, 2016

Bayer Schering Pharma announces soluble guanylyl cyclase activators

Feb. 25, 2016

Renova Therapeutics receives NIH grant to support urocortin-2 gene therapy

Feb. 25, 2016

Group in Germany patents PPARgamma antagonists

Feb. 22, 2016

Brilique 60 mg approved in E.U. for patients with history of heart attack

Feb. 19, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...